drugset / Trial / NCT00511342
Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)
RandomizedParallel-groupOpen-labelPrevention
Summary
The primary purpose of this study is to evaluate the effects of the NOMAC-E2 combined oral contraceptive (COC) on bone mineral density (BMD).
Timeline
- Start
- 2006-09
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 1.5 mg | — |
| Comparator | Levonorgestrel | Small molecule | 0.15 mg | Oral |
| Subject | Nomegestrol Acetate | Small molecule | 2.5 mg | Oral |
| Comparator | ethinyl estradiol | Small molecule | 0.03 mg | — |
Indications
No indication recorded.